

PXRD of Compound 1 Hydrochloride Salt, Hemihydrate Form III




Figure 1

DSC of Compound 1 Hydrochloride Salt, Hemihydrate Form III




Figure 2

TGA of Compound 1 Hydrochloride Salt, Hemihydrate Form III




Figure 3

DMS of Compound 1 Hydrochloride Salt, Form III




Figure 4

PXRD of Compound 1 Hydroiodide Salt, Form I




Figure 5

DSC and TGA of Compound 1 Hydroiodide Salt, Form I




Figure 6

DMS of Compound 1 Hydroiodide Salt, Form I

Adsorption/Desorption Isotherm




Figure 7

PXRD of Compound 1 Maleate Salt, Form I




Figure 8

DCS and TGA of Compound 1 Maleate Salt, Form I




Figure 9

DMS of Compound 1 Maleate Salt, Form I

Adsorption/Desorption Isotherm




Figure 10

PXRD of Compound 1 Fumarate Salt, Form I




Figure 11

DCS and TGA of Compound 1 Fumarate Salt, Form I




Figure 12

DMS of Compound 1 Fumarate Salt, Form I




Figure 13

PXRD of Compound 1 Hemifumarate Salt, Form I




Figure 14

DCS and TGA of Compound 1 Hemifumarate Salt, Form I




Figure 15

DMS of Compound 1 Hemifumarate Salt, Form I




Figure 16

PXRD of Compound 1 Orotate Salt, Form I




Figure 17

DCS and TGA of Compound 1 Orotate Salt, Form I




Figure 18

DMS of Compound 1 Orotate Salt, Form I

Adsorption/Desorption Isotherm




Figure 19

PXRD of Compound 1 Orotate Salt Hydrate, Form I




Figure 20

DCS and TGA of Compound 1 Orotate Salt Hydrate, Form I




Figure 21

DMS of Compound 1 Orotate Salt Hydrate, Form I

Adsorption/Desorption Isotherm




Figure 22

PXRD of Compound 1 Di-4-acetamidobenzoate Salt-Cocrystal Methyl Ethyl Ketone Solvate, Form I




Figure 23

DCS and TGA of Compound 1 Di-4-acetamidobenzoate Salt-Cocrystal Methyl Ethyl Ketone Solvate, Form I




Figure 24

DMS of Compound 1 Di-4-acetamidobenzoate Salt-Cocrystal Methyl Ethyl Ketone Solvate, Form I

Adsorption/Desorption Isotherm




Figure 25

PXRD of Compound 1 *trans*-Cinnamate Salt, Form I




Figure 26

DCS and TGA of Compound 1 *trans*-Cinnamate Salt, Form I




Figure 27

DMS of Compound 1 *trans*-Cinnamate Salt, Form I

Adsorption/Desorption Isotherm




Figure 28

PXRD of Compound 1 Heminapadisilate Salt, Form I




Figure 29

DCS and TGA of Compound 1 Heminapadisilate Salt, Form I




Figure 30

DMS of Compound 1 Heminapadisilate Salt, Form I

Adsorption/Desorption Isotherm




Figure 31

PXRD of Compound 1 Heminapadisilate Salt Solvate 1, Form I




Figure 32

DCS and TGA of Compound 1 Heminapadisilate Salt Solvate 1, Form I




Figure 33

PXRD of Compound 1 Heminapadisilate Salt Solvate 2, Form I




Figure 34

DCS and TGA of Compound 1 Heminapadisilate Salt Solvate 2, Form I




Figure 35

PXRD of Compound 1 ($\pm$)-Mandelate Salt Hydrate, Form I




Figure 36

DCS and TGA of Compound 1 ($\pm$)-Mandelate Salt Hydrate, Form I




Figure 37

DMS of Compound 1 (±)-Mandelate Salt Hydrate, Form I

Adsorption/Desorption Isotherm




Figure 38

PXRD of Compound 1 Hemipamoate Salt Hydrate, Form I




Figure 39

DCS and TGA of Compound 1 Hemipamoate Salt Hydrate, Form I




Figure 40

DMS of Compound 1 Hemipamoate Salt Hydrate, Form I

Adsorption/Desorption Isotherm




Figure 41

Upper Limit of Release of Compound 1 Hydrochloride Salt Hemihydrate, Form III from Modified-release
Formulation




Figure 42

Pharmacokinetics Simulation of 20-mg Modified-release Formulation and 10-mg Immediate-release (IR)

Tablets of Compound 1 Hydrochloride Salt Hemihydrate, Form III




Figure 43

Dissolution Profile of Compound 1 Hydrochloride Salt Hemihydrate, Form III Tablets Coated with
Surelease®/Opadry® (85/15)




Figure 44

Effect of the Surelease[®]/Opadry[®] Ratio on Compound 1 Hydrochloride Salt Hemihydrate, Form III Release




Figure 45

Effect of HPMC K4M Level on Compound 1 Hydrochloride Salt Hemihydrate, Form III Release




Figure 46

Effect of Surelease®/Opadry® Coating Level on Compound 1 Hydrochloride Salt Hemihydrate, Form III

Release




Figure 47

Effect of Compound 1 Hydrochloride Salt Hemihydrate, Form III Loading




Figure 48

Day 26 Efficacy of Compound 1 after PO dosed at 24 mg/kg/day or
Osmotic Pump Infusion at 15.1 mg/kg/day (Infusion Rate, 0.63 mg/kg/hr) in Fed Male SD Rats.




Figure 49

Mean Plasma Concentration of Compound 1 after PO dosed at 24 mg/kg/day or
Osmotic Pump Infusion at 15.1 mg/kg/day (Infusion Rate, 0.63 mg/kg/hr) in Fed Male SD Rats.




Figure 50

Mean AUC_{last} of Compound 1 after PO dosed at 24 mg/kg/day or
Osmotic Pump Infusion at 15.1 mg/kg/day (Infusion Rate, 0.63 mg/kg/hr) in Fed Male SD Rats.




Figure 51

Mean $C_{\max}$ of Compound 1 after PO dosed at 24 mg/kg/day or
Osmotic Pump Infusion at 15.1 mg/kg/day (Infusion Rate, 0.63 mg/kg/hr) in Fed Male SD Rats.




Figure 52

Individual Compound 1 Exposure Values after PO (24 mg/kg/day) or SC Osmotic Pump Infusion (15.1 mg/kg/day, Infusion Rate, 0.63 mg/kg/h) in Fed Male SD Rats.




Figure 53

Days 1-26 Efficacy of Compound 1 after PO dosed at 24 mg/kg/day or
Osmotic Pump Infusion at 15.1 mg/kg/day (Infusion Rate, 0.63 mg/kg/hr) in Fed Male SD Rats




Figure 54

Dissolution Profiles of Compound 1 Hydrochloride Salt, Hemihydrate Form III 20-mg Modified-release
Formulations with Soluble Coating




Figure 55

Dissolution Profiles of Compound 1 Hydrochloride Salt, Hemihydrate Form III 20-mg Modified-release

Formulations with Functional Polymer Coating




Figure 56

Immediate-Release Mean Plasma Compound 1 Concentrations Versus Time on Day 1 in Humans




Figure 57

Immediate-Release Mean Plasma Compound 1 Concentrations Versus Time on Day 14 in Humans




Figure 58